Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We ...

The FDA has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.

Brelovitug has previously received Orphan and PRIME designation from the European Medicines Agency.

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.

The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the ...

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...

A revolutionary advancement in cancer treatment at UH Seidman Cancer Center is dramatically reducing the time patients spend ...

Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products ...

What You Need to Know The global hydrogen water market is projected to grow from USD 2.5 billion in 2024 to USD 4.35 billion ...